Clinical trial NCT00641732: Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement
Official title: A Phase 2, Randomized, Active Comparator-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Venous Thromboembolism
Keywords: venous thromboembolism
oral anticoagulant
direct factor Xa inhibitor
total knee replacement
drug therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2008-03-24
Enrollment: 1045
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine if TAK-442, once daily (QD) or twice daily (BID), is as safe and effective as enoxaparin in preventing the development of blood clots after knee replacement surgery.

Detailed description: Takeda Global Research \& Development Center, Inc. is developing the compound TAK-442 as a candidate for the secondary prevention of atherothrombotic events in patients with acute coronary syndromes. TAK-442 is an oral inhibitor of activated factor X within the blood coagulation cascade.

Due to its critical role in propagating the coagulation cascade, activated factor X is now considered to be a therapeutic aim in the development of anticoagulant drugs. Therefore activated factor X inhibitors, are among the agents under investigation as treatments for the spectrum of thromboembolic diseases involving either the arterial or the venous system.

Short term anticoagulation is often used for the prevention of venous thromboembolism. Patients undergoing major orthopedic surgery are at particularly high risk of venous thromboembolism after surgery. Consequently, such patients are routinely given anticoagulant medication after surgery. Although parenteral (injectable) drugs, such as enoxaparin or fondaparinux, can be used for this indication, the need for subcutaneous injection is problematic once patients are discharged from hospital. With the push for shorter hospital stays, this issue is of increasing concern. Therefore, there is a need for new oral anticoagulants. Although warfarin can be used for out of hospital prophylaxis, the need for coagulation monitoring and dose adjustments complicates its use. The new oral anticoagulants have the potential to overcome this problem because they can be given in fixed doses without the need for coagulation monitoring.

The purpose of the current study is to evaluate the antithrombotic effect of TAK-442 in patients undergoing elective total knee replacement surgery. This study will be the first TAK-442 trial in patients.

Individuals who want to participate in this study will be required to provide written informed consent. Study participation is anticipated to be approximately 2.25 months. Multiple procedures will occur at each visit which may include fasting, blood collection, urine collection, physical examinations, electrocardiograms and bilateral venogram. Outside of the study center, participants randomized to enoxaparin will be required to administer study medication subcutaneously with a syringe.

Eligibility criteria: Inclusion Criteria

* Scheduled to undergo elective, unilateral, primary, total knee replacement.
* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
* Screening laboratory tests (including clinical chemistry, hematology, and complete urinalysis) are within the reference range for the testing laboratory or are determined not to compromise subject safety by the investigator.

Exclusion Criteria

* Received TAK-442 in a previous clinical study or as a therapeutic agent.
* Body weight greater than 150 kg.
* Known bleeding diathesis (including Von Willebrand's disease or Hemophilia A or B).
* History of intracerebral, intraocular, or gastrointestinal bleeding, or active gastric or duodenal ulceration, within the 6 months prior to Randomization.
* Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including throughout the treatment period of the study due to an increased risk of bleeding, and should be stopped at least 5 days prior to surgery and in accordance with the product information:

  * Parenteral anticoagulants
  * Unfractionated heparin
  * Low molecular weight heparin (eg, dalteparin, non-study enoxaparin)
  * Direct thrombin inhibitors (eg, bivalirudin, argatroban)
  * Factor Xa inhibitors (eg, fondaparinux)
  * Oral anticoagulants
  * Warfarin
  * Anisindione
  * Antiplatelet drugs
  * Aspirin greater than 162 mg/day
  * Clopidogrel
  * Ticlopidine
  * Cilostazol
  * Dipyridamole
  * Glycoprotein IIb/IIIa inhibitors (eg, abciximab, eptifibatide)
  * NSAIDs with a half life greater than or equal to 17 hours
  * Meloxicam
  * Fibrinolytic agents
  * tPA (alteplase, reteplase, tenecteplase)
* History of major surgery within 3 months prior to randomization; or deep vein thrombosis, pulmonary embolism, myocardial infarction, cerebrovascular accident, or transient ischemic attack within 6 months prior to randomization.
* History of hypersensitivity or allergies to other activated factor X inhibitors or enoxaparin (or other low molecular weight heparins).
* Condition prohibiting bilateral venography.
* Has had multiple or traumatic epidural or spinal punctures immediately prior to randomization (defined as grossly bloody or greater than 3 attempted cannulations).
* Requires use of an indwelling epidural catheter for post-operative analgesia.
* Severe hypertension defined as systolic blood pressure greater than 180 mmHg or diastolic blood pressure greater than 110 mmHg at Screening.
* Moderate to severe renal dysfunction or disease (based on calculated creatinine clearance less than 45 mL/min/1.73 m2) at Screening.
* Alanine aminotransferase level greater than 2.0 times the upper limit of normal, active liver disease, or jaundice at Screening.
* Anemia (hemoglobin less than 10.0 g per dL) or thrombocytopenia (platelet count less than 100 times 103 per uL) at screening.
* Taking aspirin greater than 162 mg per day.
* Abuses drugs (defined as any illicit drug use) or alcohol.
* History of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. (This criterion does not include those subjects with basal cell or Stage 1 squamous cell carcinoma of the skin.)
* Currently participating in another investigational study or has participated in an investigational study within 30 days prior to Screening.
* Any other serious disease or condition at Screening or Randomization that would compromise subject safety or make it difficult to successfully manage and follow the subject according to the protocol.
* Requires the use of pneumatic compression post-operatively.
* Known inherited thrombophilic disorder such as the factor V Leiden or prothrombin gene mutations or deficiencies of antithrombin, protein C, or protein S.

Primary outcomes:
measure: Composite evaluation of All-Cause Mortality, Symptomatic and Asymptomatic Deep Vein Thrombosis and Symptomatic Pulmonary Embolism.
timeFrame: Day 10.
measure: Incidence of Major Bleeding.
timeFrame: Day 10.
Secondary outcomes:
measure: Evaluation of Major Venous Thromboembolism (composite of Symptomatic or Asymptomatic Proximal Deep Vein Thrombosis, Symptomatic Objectively Confirmed Pulmonary Embolism, and Venous Thromboembolism-Related Death).
timeFrame: Day 10.
measure: Evaluation of Symptomatic Venous Thromboembolism.
timeFrame: Day 10.
measure: Evaluation of Proximal Deep Vein Thrombosis.
timeFrame: Day 10.
measure: Evaluation of Distal Deep Vein Thrombosis.
timeFrame: Day 10.
measure: Evaluation of clinically significant Non-Major Bleeding events.
timeFrame: Day 10.
measure: Evaluation of Minor Bleeding events.
timeFrame: Day 10.
Other outcomes:
Locations:
city: Birmingham
country: United States
state: Alabama
city: Tuscaloosa
country: United States
state: Alabama
city: Phoenix
country: United States
state: Arizona
city: Little Rock
country: United States
state: Arkansas
city: Bakersfield
country: United States
state: California
city: Fountain Valley
country: United States
state: California
city: Long Beach
country: United States
state: California
city: Montclair
country: United States
state: California
city: Oceanside
country: United States
state: California
city: Vista
country: United States
state: California
city: Yuba City
country: United States
state: California
city: Aurora
country: United States
state: Colorado
city: Centennial
country: United States
state: Colorado
city: Denver
country: United States
state: Colorado
city: Bay Pines
country: United States
state: Florida
city: Clearwater
country: United States
state: Florida
city: DeLand
country: United States
state: Florida
city: Gulf Breeze
country: United States
state: Florida
city: Hollywood
country: United States
state: Florida
city: Pinellas Park
country: United States
state: Florida
city: Tamarac
country: United States
state: Florida
city: Atlanta
country: United States
state: Georgia
city: Boise
country: United States
state: Idaho
city: Meridian
country: United States
state: Idaho
city: Springfield
country: United States
state: Illinois
city: Towson
country: United States
state: Maryland
city: Charlotte
country: United States
state: North Carolina
city: Greensboro
country: United States
state: North Carolina
city: Cincinnati
country: United States
state: Ohio
city: Tulsa
country: United States
state: Oklahoma
city: Altoona
country: United States
state: Pennsylvania
city: Johnstown
country: United States
state: Pennsylvania
city: Charleston
country: United States
state: South Carolina
city: Dallas
country: United States
state: Texas
city: Grapenne
country: United States
state: Texas
city: Lubbock
country: United States
state: Texas
city: San Antonio
country: United States
state: Texas
city: Spokane
country: United States
state: Washington
city: Edmonton
country: Canada
state: Alberta
city: Red Deer
country: Canada
state: Alberta
city: Kelowna
country: Canada
state: British Columbia
city: Winnipeg
country: Canada
state: Manitoba
city: Fredericton
country: Canada
state: New Brunswick
city: St. John
country: Canada
state: New Brunswick
city: Dartmouth
country: Canada
state: Nova Scotia
city: Ajax
country: Canada
state: Ontario
city: Burlington
country: Canada
state: Ontario
city: Cambridge
country: Canada
state: Ontario
city: Chatham
country: Canada
state: Ontario
city: Guelph
country: Canada
state: Ontario
city: Kitchener
country: Canada
state: Ontario
city: Newmarket
country: Canada
state: Ontario
city: Niagra Falls
country: Canada
state: Ontario
city: Oakville
country: Canada
state: Ontario
city: Oshawa
country: Canada
state: Ontario
city: Ottawa
country: Canada
state: Ontario
city: Sarnia
country: Canada
state: Ontario
city: Scarborough
country: Canada
state: Ontario
city: St. Catherines
country: Canada
state: Ontario
city: Sudbury
country: Canada
state: Ontario
city: Thunder Bay
country: Canada
state: Ontario
city: Windsor
country: Canada
state: Ontario
city: Montreal
country: Canada
state: Quebec
city: Charlottetown
country: Canada
Study officials:
affiliation: Takeda
name: Executive Medical Director Clinical Science
role: STUDY_DIRECTOR
References:
citation: Weitz JI, Cao C, Eriksson BI, Fisher W, Kupfer S, Raskob G, Spaeder J, Turpie AG. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010 Dec;104(6):1150-7. doi: 10.1160/TH10-05-0273. Epub 2010 Sep 30.